Hsa_circ_0003645 Promotes Breast Cancer Progression by Regulating miR-139-3p/HMGB1 Axis

References

• Anastasiadi Z, Lianos GD, Ignatiadou E, et al. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313–317. doi:10.1007/s13304-017-0424-128260181
   PubMed Web of Science ®Google Scholar
• Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.31456179
   PubMed Web of Science ®Google Scholar
• Moon PG, Lee JE, Cho YE, et al. Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection. Clin Cancer Res. 2016;22(7):1757–1766. doi:10.1158/1078-0432.CCR-15-065426603257
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–146.22356776
   PubMed Web of Science ®Google Scholar
• Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602–1612. doi:10.1002/ijc.2779922927033
   PubMed Web of Science ®Google Scholar
• Inns J, James V. Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. Breast. 2015;24(4):364–369.25957467
   PubMed Web of Science ®Google Scholar
• Guo JU, Agarwal V, Guo H, et al. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15(7):409. doi:10.1186/s13059-014-0409-z25070500
   PubMed Web of Science ®Google Scholar
• Barrett SP, Wang PL, Salzman J. Circular RNA biogenesis can proceed through an exon-containing lariat precursor. Elife. 2015;4:e07540. doi:10.7554/eLife.0754026057830
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–157. doi:10.1261/rna.035667.11223249747
   PubMed Web of Science ®Google Scholar
• Holdt LM, Kohlmaier A, Teupser D. Molecular roles and function of circular RNAs in eukaryotic cells. Cell Mol Life Sci. 2018;75(6):1071–1098.29116363
   PubMed Web of Science ®Google Scholar
• Du W, Li D, Guo X, et al. Circ-PRMT5 promotes gastric cancer progression by sponging miR-145 and miR-1304 to upregulate MYC. Artif Cells Nanomed Biotechnol. 2019;47(1):4120–4130. doi:10.1080/21691401.2019.167185731701767
   PubMed Web of Science ®Google Scholar
• Salzman J, Chen RE, Olsen MN, et al. Cell-type specific features of circular RNA expression. PLoS Genet. 2013;9(9):e1003777. doi:10.1371/journal.pgen.100377724039610
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338. doi:10.1038/nature1192823446348
   PubMed Web of Science ®Google Scholar
• Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66. doi:10.1016/j.molcel.2014.08.01925242144
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–369. doi:10.1080/15476286.2017.127978828080204
   PubMed Web of Science ®Google Scholar
• Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44(6):2846–2858. doi:10.1093/nar/gkw02726861625
   PubMed Web of Science ®Google Scholar
• Li Z, Huang C, Bao C, et al. Corrigendum: exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2017;24(2):194. doi:10.1038/nsmb0217-194a
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Y, Zhao L, et al. Circular RNAMTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018;53(4):1752–1762.30015883
   PubMed Web of Science ®Google Scholar
• Huang G, Li S, Yang N, et al. Recent progress in circular RNAs in human cancers. Cancer Lett. 2017;404:8–18. doi:10.1016/j.canlet.2017.07.00228705773
   PubMed Web of Science ®Google Scholar
• Zhong Z, Huang M, Lv M, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;403:305–317. doi:10.1016/j.canlet.2017.06.02728687357
   PubMed Web of Science ®Google Scholar
• An J, Shi H, Zhang N, et al. Elevation of circular RNA circ_0003645 forecasts unfavorable prognosis and facilitates cell progression via miR-1179/TMEM14A pathway in non-small cell lung cancer. Biochem Biophys Res Commun. 2019;511(4):921–925. doi:10.1016/j.bbrc.2019.03.01130853176
   PubMed Web of Science ®Google Scholar
• Shi L, Yuan Y, Li HY. MicroRNA-139-3p suppresses growth and metastasis of glioblastoma via inhibition of NIN1/RPNI2 binding protein 1 homolog. Eur Rev Med Pharmacol Sci. 2019;23(10):4264–4274.31173298
   PubMed Web of Science ®Google Scholar
• Tian W, Wu W, Li X, et al. MiRNA-139-3p inhibits the proliferation, invasion, and migration of human glioma cells by targeting MDA-9/syntenin. Biochem Biophys Res Commun. 2019;508(1):295–301. doi:10.1016/j.bbrc.2018.11.14430502089
   PubMed Web of Science ®Google Scholar
• Zou ZC, Dai M, Huang ZY, et al. MicroRNA-139-3p suppresses tumor growth and metastasis in hepatocellular carcinoma by repressing ANXA2R. Oncol Res. 2018. doi:10.3727/096504018X15178798885361
   Web of Science ®Google Scholar
• Huang P, Xi J, Liu S. MiR-139-3p induces cell apoptosis and inhibits metastasis of cervical cancer by targeting NOB1. Biomed Pharmacother. 2016;83:850–856. doi:10.1016/j.biopha.2016.07.05027505862
   PubMed Web of Science ®Google Scholar
• Xu JZ, Shao CC, Wang XJ, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis. 2019;10(3):175. doi:10.1038/s41419-019-1382-y30787278
   PubMed Web of Science ®Google Scholar
• Feng H, Gu ZY, Li Q, et al. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 2019;12(1):35. doi:10.1186/s13048-019-0508-231010415
   PubMed Web of Science ®Google Scholar
• Wu Z, Huang W, Wang X, et al. Circular RNA CEP128 acts as a sponge of miR-145-5p in promoting the bladder cancer progression via regulating SOX11. Mol Med. 2018;24(1):40. doi:10.1186/s10020-018-0039-030134837
   PubMed Web of Science ®Google Scholar
• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.05929625059
   PubMed Web of Science ®Google Scholar
• Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016;143(11):1838–1847.27246710
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang J, Zhao F. CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 2015;16:4. doi:10.1186/s13059-014-0571-325583365
   PubMed Web of Science ®Google Scholar
• Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 2015;444:132–136. doi:10.1016/j.cca.2015.02.01825689795
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Huang L, et al. Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances. Int J Clin Exp Pathol. 2015;8(12):16020–16025.26884878
   PubMed Web of Science ®Google Scholar
• Qin M, Liu G, Huo X, et al. Hsa_circ_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 2016;16(1):161–169. doi:10.3233/CBM-15055226600397
   PubMed Web of Science ®Google Scholar
• Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–1134. doi:10.1016/j.cell.2015.02.01425768908
   PubMed Web of Science ®Google Scholar
• Guarnerio J, Bezzi M, Jeong JC, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell. 2016;166(4):1055–1056.
   PubMedGoogle Scholar
• Ahmed I, Karedath T, Andrews SS, et al. Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget. 2016;7(24):36366–36381. doi:10.18632/oncotarget.891727119352
   PubMedGoogle Scholar
• Huang M, Zhong Z, Lv M, et al. Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma. Oncotarget. 2016;7(30):47186–47200. doi:10.18632/oncotarget.970627363013
   PubMedGoogle Scholar
• Sand M, Bechara FG, Gambichler T, et al. Circular RNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci. 2016;83(3):210–218. doi:10.1016/j.jdermsci.2016.05.01227298156
   PubMed Web of Science ®Google Scholar
• Wang Y, Hou J, He D, et al. The emerging function and mechanism of ceRNAs in cancer. Trends Genet. 2016;32(4):211–224. doi:10.1016/j.tig.2016.02.00126922301
   PubMed Web of Science ®Google Scholar
• Li X, Diao H. Circular RNA circ_0001946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR-671-5p and CDR1. J Cell Physiol. 2019;234(8):13807–13819.30663767
   PubMed Web of Science ®Google Scholar
• Huo LW, Wang YF, Bai XB, et al. circKIF4A promotes tumorogenesis of glioma by targeting miR-139-3p to activate Wnt5a signaling. Mol Med. 2020;26(1):29. doi:10.1186/s10020-020-00159-132268875
   PubMed Web of Science ®Google Scholar
• Ng L, Wan TM, Man JH, et al. Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer. Oncotarget. 2017;8(16):27393–27400. doi:10.18632/oncotarget.1617128404964
   PubMedGoogle Scholar
• Yonemori M, Seki N, Yoshino H, et al. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 2016;107(9):1233–1242. doi:10.1111/cas.1300227355528
   PubMed Web of Science ®Google Scholar
• Xue F, Li QR, Xu YH, et al. MicroRNA-139-3p inhibits the growth and metastasis of ovarian cancer by inhibiting ELAVL1. Onco Targets Ther. 2019;12:8935–8945. doi:10.2147/OTT.S21073931806990
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liu J, Quan J, et al. MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta-analysis. Cancer Sci. 2018;109(9):2651–2659. doi:10.1111/cas.1371429949235
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013;258(3):400–408. doi:10.1097/SLA.0b013e3182a15bcc24022433
   PubMed Web of Science ®Google Scholar
• Wang X, Gao J, Zhou B, et al. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Life Sci. 2019;232:116596. doi:10.1016/j.lfs.2019.11659631233760
   PubMed Web of Science ®Google Scholar
• Sannigrahi MK, Sharma R, Singh V, et al. Role of host miRNA Hsa-miR-139-3p in HPV-16-induced carcinomas. Clin Cancer Res. 2017;23(14):3884–3895. doi:10.1158/1078-0432.CCR-16-293628143871
   PubMed Web of Science ®Google Scholar
• Ueda T, Chou H, Kawase T, et al. Acidic C-tail of HMGB1 is required for its target binding to nucleosome linker DNA and transcription stimulation. Biochemistry. 2004;43(30):9901–9908. doi:10.1021/bi035975l15274644
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251. doi:10.1126/science.285.5425.24810398600
   PubMed Web of Science ®Google Scholar
• Janko C, Filipovic M, Munoz LE, et al. Redox modulation of HMGB1-related signaling. Antioxid Redox Signal. 2014;20(7):1075–1085. doi:10.1089/ars.2013.517923373897
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Zeh HJ, et al. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14(7):1315–1335. doi:10.1089/ars.2010.335620969478
   PubMed Web of Science ®Google Scholar
• Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209(9):1519–1528. doi:10.1084/jem.2012018922869893
   PubMed Web of Science ®Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162.21219181
   PubMed Web of Science ®Google Scholar
• Chang BP, Wang DS, Xing JW, et al. miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. J Huazhong Univ Sci Technol Med Sci. 2014;34(2):201–206. doi:10.1007/s11596-014-1259-3
   PubMedGoogle Scholar
• Wu L, Yang L. The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications. Oncol Lett. 2018;15(5):6799–6805.29725415
   PubMed Web of Science ®Google Scholar